Literature DB >> 35941258

How to confront the high prevalence of pulmonary micro nodules (PMNs) in osteosarcoma patients?

Zhenyu Cai1, Jie Xu1, Xin Sun1, Ranxin Zhang1, Lu Xie1, Jichuan Wang1, Xiaodong Tang1, Rongli Yang1, Wei Guo2.   

Abstract

PURPOSE: Pulmonary metastasis was a negative factor of osteosarcoma prognosis. However, there is no universal criteria to confirm pulmonary metastasis at pulmonary micro nodule (PMN, Dmax ≤ 5 mm) stage other than pathology. We aimed to identify prevalence of PMNs, determine prognosis of osteosarcoma with PMNs, and analyze risk factors related to PMN progression.
METHODS: We retrospectively reviewed 425 consecutive osteosarcoma patients. According to dynamic change in size and number of PMNs, patients were divided into PMN progression and non-progression group. Demographic data, initial laboratory data, radiological features, and oncological evaluations were analyzed. Cox regression was used to identify risk factors for PMN progression. Overall survival rate was measured and analyzed with Kaplan-Meier method. Differences with p < 0.05 were considered significant.
RESULTS: PMNs were found in 74% (315/425) osteosarcoma patients, half of whom (157/315) suffering PMN progression. Overall survival rate was 70.2%, while survival rates for PMN progression group and non-progression group were 53.40% and 87.40%, respectively. Clinical risk factors for PMN progression in certain patients included blood vessel invasion, extrapulmonary metastases, low tumour cell necrosis rate, and large tumour size. Radiologic risk factors included greatest diameter, distance to pleura, CT value, solid components, and smooth border.
CONCLUSION: PMN is quite common in osteosarcoma patients. PMN progression is related to both certain clinical and radiological factors, which could assist surgeons to determine its possibility to progress at an early stage.
© 2022. The Author(s) under exclusive licence to SICOT aisbl.

Entities:  

Keywords:  Osteosarcoma; Prognosis; Progression; Pulmonary micro nodule; Risk factor

Mesh:

Year:  2022        PMID: 35941258     DOI: 10.1007/s00264-022-05534-7

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.479


  35 in total

1.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Pulmonary Nodule Size <5 mm Still Warrants Investigation in Patients With Osteosarcoma and Ewing Sarcoma.

Authors:  Jared Kusma; Cody Young; Han Yin; Joseph R Stanek; Nicholas Yeager; Jennifer H Aldrink
Journal:  J Pediatr Hematol Oncol       Date:  2017-04       Impact factor: 1.289

3.  Indeterminate Pulmonary Nodules in Osteosarcoma Are Associated With Increased Risk of Pulmonary Metastasis.

Authors:  Komal Seher; Haleema Saeed; Tooba Kareem; Ali S Baqari; Imran Niazi; Rabia M Wali
Journal:  J Pediatr Hematol Oncol       Date:  2021-03-03       Impact factor: 1.289

4.  Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

Authors:  Katherine A Janeway; Donald A Barkauskas; Mark D Krailo; Paul A Meyers; Cindy L Schwartz; David H Ebb; Nita L Seibel; Holcombe E Grier; Richard Gorlick; Neyssa Marina
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

5.  What Is the Clinical Importance of Incidental Findings on Staging CT Scans in Patients With Sarcoma?

Authors:  Zachary Mayo; Sean Kennedy; Yubo Gao; Benjamin J Miller
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

6.  Survival in high-grade osteosarcoma: improvement over 21 years at a single institution.

Authors:  P Picci; M Mercuri; S Ferrari; M Alberghini; A Briccoli; C Ferrari; E Pignotti; G Bacci
Journal:  Ann Oncol       Date:  2009-11-04       Impact factor: 32.976

7.  Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study.

Authors:  Koichi Ogura; Tomohiro Fujiwara; Hideo Yasunaga; Hiroki Matsui; Dae-Geun Jeon; Wan Hyeong Cho; Hiroaki Hiraga; Takeshi Ishii; Tsukasa Yonemoto; Hiroto Kamoda; Toshifumi Ozaki; Eiji Kozawa; Yoshihiro Nishida; Hideo Morioka; Toru Hiruma; Shigeki Kakunaga; Takafumi Ueda; Yusuke Tsuda; Hirotaka Kawano; Akira Kawai
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

8.  Computerized texture analysis of pulmonary nodules in pediatric patients with osteosarcoma: Differentiation of pulmonary metastases from non-metastatic nodules.

Authors:  Yeon Jin Cho; Woo Sun Kim; Young Hun Choi; Ji Young Ha; SeungHyun Lee; Sang Joon Park; Jung-Eun Cheon; Hyoung Jin Kang; Hee Young Shin; In-One Kim
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

9.  How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?

Authors:  Kim M Tsoi; Martin Lowe; Yusuke Tsuda; Johnathan R Lex; Tomohiro Fujiwara; Ghassan Almeer; Jonathan Gregory; Jonathan Stevenson; Scott E Evans; Rajesh Botchu; Lee M Jeys
Journal:  Clin Orthop Relat Res       Date:  2021-02-01       Impact factor: 4.755

10.  Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.

Authors:  Sigbjørn Smeland; Stefan S Bielack; Jeremy Whelan; Mark Bernstein; Pancras Hogendoorn; Mark D Krailo; Richard Gorlick; Katherine A Janeway; Fiona C Ingleby; Jakob Anninga; Imre Antal; Carola Arndt; Ken L B Brown; Trude Butterfass-Bahloul; Gabriele Calaminus; Michael Capra; Catharina Dhooge; Mikael Eriksson; Adrienne M Flanagan; Godehard Friedel; Mark C Gebhardt; Hans Gelderblom; Robert Goldsby; Holcombe E Grier; Robert Grimer; Douglas S Hawkins; Stefanie Hecker-Nolting; Kirsten Sundby Hall; Michael S Isakoff; Gordana Jovic; Thomas Kühne; Leo Kager; Thekla von Kalle; Edita Kabickova; Susanna Lang; Ching C Lau; Patrick J Leavey; Stephen L Lessnick; Leo Mascarenhas; Regine Mayer-Steinacker; Paul A Meyers; Raj Nagarajan; R Lor Randall; Peter Reichardt; Marleen Renard; Catherine Rechnitzer; Cindy L Schwartz; Sandra Strauss; Lisa Teot; Beate Timmermann; Matthew R Sydes; Neyssa Marina
Journal:  Eur J Cancer       Date:  2019-01-25       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.